<DOC>
	<DOCNO>NCT01635465</DOCNO>
	<brief_summary>Docetaxel plus Capecitabine anthracycline-pretreated metastatic breast cancer recommend scheme National Comprehensive Cancer Network ( NCCN ) guideline . Vinorelbine plus Capecitabine also effective Metastatic Breast Cancer ( MBC ) clinical study small sample .</brief_summary>
	<brief_title>Vinorelbine Plus Capecitabine Versus Docetaxel Plus Capecitabine Anthracycline-pretreated Women With Metastatic Breast Cancer</brief_title>
	<detailed_description>A randomise control trial vinorelbine plus capecitabine versus docetaxel plus capecitabine anthracycline-pretreated woman metastatic breast cancer . The primary endpoint study progression free survival ( PFS ) . The secondary endpoint overall response rate ( ORR ) , overall survival ( OS ) safety .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<criteria>female â‰¥ 18 year old ECOG 02 brain metastasis</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>